Lipid-polymer hybrid nanoparticles loaded with N -acetylcysteine for the modulation of neuroinflammatory biomarkers in human iPSC-derived PSEN2 (N141I) astrocytes as a model of Alzheimer's disease

• Published in: Journal of materials chemistry. B, Materials for biology and medicine Vol. 12; no. 21; pp. 5085 - 5097
• Main Authors: Vargas-Barona, Alondra, Bernáldez-Sarabia, Johanna, Castro-Ceseña, Ana B
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 29.05.2024
• Subjects: Acetylcysteine; Alzheimer's disease; Amyloid precursor protein; Astrocytes; Bioavailability; Biomarkers; Blood-brain barrier; Cell culture; Cognitive ability; Cytokines; Drug delivery; Drug development; Gene expression; Glial cells; Glial fibrillary acidic protein; Global health; IL-1β; Inflammation; Interleukin 6; Interleukins; Lipids; Lipopolysaccharides; Nanoparticles; Nanotechnology; Neurodegenerative diseases; Neuromodulation; Permeability; Pluripotency; Polymers; Proteins; Public health; Stem cells; Transferrin; β-Amyloid; γ-Interferon
• ISSN: 2050-750X; 2050-7518
• DOI: 10.1039/d4tb00521j

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive impairment associated with the accumulation of beta-amyloid protein (Aβ). Aβ activates glial cells in the brain, increasing the secretion of proinflammatory cytokines, which leads to neuroinflammation and neuronal death. Currently, there are no effective treatments that cure or stop its progression; therefore, AD is considered a global health priority. The main limitations are the low drug bioavailability and impermeability of the blood-brain barrier (BBB). Fortunately, nanomedicine has emerged as a promising field for the development of new nanosystems for the controlled and targeted delivery of drugs to the brain. Therefore, in this work, lipid-polymer hybrid nanoparticles (LPHNPs) conjugated with transferrin (Tf) to facilitate crossing the BBB and loaded with -acetylcysteine (NAC) for its anti-inflammatory effect were synthesized, and their physicochemical characterization was carried out. Subsequently, an model involving human astrocytes derived from induced pluripotent stem cells (iPSC) from an AD-diagnosed patient was developed, which was brought to a reactive state by stimulation with lipopolysaccharides (LPSs). The cell culture was treated with either Tf-conjugated LPHNPs loaded with NAC (NAC-Tf-LPHNPs) at 0.25 mg mL , or free NAC at 5 mM. The results showed that NAC-Tf-LPHNPs favorably modulated the expression of proinflammatory genes such as interleukin-1β (IL-1β), amyloid precursor protein (APP) and glial fibrillary acidic protein (GFAP). In addition, they reduced the secretion of the proinflammatory cytokines interleukin 6 (IL-6), IL-1β and interferon-gamma (INF-γ). Results for both cases were compared to the group of cells that did not receive any treatment. In contrast, free NAC only had this effect on the expression of IL-1β and the secretion of the cytokines IL-6 and INF-γ. These results indicate the potential of NAC-Tf-LPHNPs for AD treatment.